Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
Denise M. Wolf, Laura van ‘t Veer, Zelos Zhu(University of California, San Francisco), Lajos Pusztai(Yale University), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Lamorna Brown Swigart(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Minetta C. Liu(Mayo Clinic), Julia Wulfkuhle(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Laura Sit(Memorial Sloan Kettering Cancer Center), Smita Asare(Quantum Leap Healthcare Collaborative), Amrita Basu(University of Calcutta), Amy L. Delson(Children's Advocacy Center), Rosa I. Gallagher(George Mason University), Ruixiao Lu(Quantum Leap Healthcare Collaborative), Pei Rong Evelyn Lee, Christina Yau(Hospital Authority), Jeffrey B. Matthews(University of California, San Francisco), Mark Jesus M. Magbanua(University of California, San Francisco), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Laura J. Esserman(University of California, San Francisco), Donald A. Berry(Berry & Associates (United States)), Rosalyn W. Sayaman(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Nicholas O’Grady(University of California, San Francisco), Hope S. Rugo(City of Hope), Jerome J. Braun(Quantum Leap Healthcare Collaborative), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Jean Philippe Coppé(University of California, San Francisco), Angela DeMichele(University of Pennsylvania)
Cited by 335
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k